---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-062795"
form_type: "8-K"
ticker: "VTR"
cik: "0000740260"
company_name: "Ventas, Inc."
filed_at: "2026-05-15T21:15:38+00:00"
generated_at: "2026-05-15T21:16:16.166194+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ventas ups ATM equity capacity to $3.0B; all 12 directors elected at annual meeting

## Summary
- Amendment No. 3 to ATM Sales Agreement raises aggregate gross sales price to $3.0B, excluding prior sales.
- Annual meeting had 93.5% voter turnout; all 12 director nominees elected with majority votes.
- Say-on-pay proposal approved with 91.6% of votes cast in favor; KPMG ratification passed.
- EVP Peter J. Bulgarelli retired May 1, 2026; separation agreement provides prorated 2026 bonus subject to release and restrictive covenants.

## SEC filing metadata
- accession: 0001104659-26-062795
- form_type: 8-K
- ticker: VTR
- cik: 0000740260
- company_name: Ventas, Inc.
- filed_at: 2026-05-15T21:15:38+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 5.07, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/740260/000110465926062795/0001104659-26-062795-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/740260/000110465926062795/tm2614646d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-062795
- JSON: https://secwatch.observer/filing/0001104659-26-062795.json
- Plain text: https://secwatch.observer/filing/0001104659-26-062795.txt

## Key facts
- Executive change
  Peter J. Bulgarelli retired as Executive Vice President, Outpatient Medical & Research at Ventas, Inc..
  - Action: retired
  - Role: Executive Vice President, Outpatient Medical & Research
  source text: On May 12, 2026, in connection with his previously disclosed retirement on May 1, 2026, Ventas, Inc. (the “Company”) entered into a separation and release agreement with Peter J. Bulgarelli, Executive Vice President, Outpatient Medical & Research, Ventas, Inc. and President and CEO, Lillibridge Healthcare Services, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/740260/000110465926062795/0001104659-26-062795-index.htm
- Shareholder Votes
  Ventas, Inc. shareholders approved To ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year at the 2026-05-13 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-05-13
  source text: Proposal 3: To ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year
  evidence_url: https://www.sec.gov/Archives/edgar/data/740260/000110465926062795/0001104659-26-062795-index.htm
- Shareholder Votes
  Ventas, Inc. shareholders approved To approve, on an advisory basis, the compensation of the Company’s Named Executive Officers at the 2026-05-13 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-05-13
  source text: Proposal 2: To approve, on an advisory basis, the compensation of the Company’s Named Executive Officers
  evidence_url: https://www.sec.gov/Archives/edgar/data/740260/000110465926062795/0001104659-26-062795-index.htm
- Shareholder Votes
  Ventas, Inc. shareholders approved To elect the 12 director nominees named in the Proxy Statement to serve until the 2027 Annual Meeting of Stockholders at the 2026-05-13 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-05-13
  source text: Proposal 1: To elect the 12 director nominees named in the Proxy Statement to serve until the 2027 Annual Meeting of Stockholders
  evidence_url: https://www.sec.gov/Archives/edgar/data/740260/000110465926062795/0001104659-26-062795-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.